With a New Identity, Travere Thearpeutics Seeks to Find Its True Path
The rare disease drug developer Retrophin has been through a number of changes in recent years including a new CEO, a late-stage failure of a key program, and the resolution of dueling lawsuits between it and its former CEO and convicted fraudster Martin Shkreli. Now with data from its lead experimental therapy sparsentan expected next year in two different rare kidney diseases, the company has changed its name to Travere Therapeutics. We spoke to Eric Dube, CEO of Travere, about the company’s new identity, its experimental therapy sparsentan, and the rare kidney diseases it is being developed to treat.
Create your
podcast in
minutes
It is Free